BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15855198)

  • 1. Two cases of delayed cyclosporin absorption leading to CsA exposure higher than that predicted by C2 monitoring alone.
    Yu R; Chadban S; Svara F; Sen S; Eris J
    Nephrol Dial Transplant; 2005 Aug; 20(8):1745-7. PubMed ID: 15855198
    [No Abstract]   [Full Text] [Related]  

  • 2. Problems of cyclosporine absorption profiling using C2-monitoring.
    Schuetz M; Einecke G; Mai I; Neumayer HH; Glander P; Waiser J; Fritsche L; Budde K
    Eur J Med Res; 2005 Apr; 10(4):175-8. PubMed ID: 15946914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adults renal recipients receiving ketoconazole.
    Videla C; Vega J; Borja H
    Transplant Proc; 2005 Apr; 37(3):1574-6. PubMed ID: 15866677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
    Bunnag S; Vareesangthip K; Ong-ajyooth L
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients.
    Cattaneo D; Merlini S; Baldelli S; Bartolini B; Nicastri A; Gotti E; Remuzzi G; Perico N
    Ther Drug Monit; 2006 Oct; 28(5):643-9. PubMed ID: 17038879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine.
    Hecking M; Kainz A; Schillinger M; Posch C; Birsan T; Rasoul-Rockenschaub S; Böhmig GA; Schmaldienst S; Watschinger B; Hörl WH; Mühlbacher F; Säemann MD
    Transpl Int; 2008 Mar; 21(3):223-33. PubMed ID: 17903183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P; Ortiz AM; Jara A; Vilches S
    Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
    Strong DK; Lai A; Primmett D; White CT; Lirenman DS; Carter JE; Hurley RM; Virji M; Ensom MH
    Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
    Domínguez J; Fuenzalida D; Norambuena R; Pais E; Cortes Monroy G; Llanos R
    Transplant Proc; 2005 Apr; 37(3):1583-5. PubMed ID: 15866680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation.
    Wacke R; Kundt G; Gock M; Klar E; Drewelow B; Schareck W
    Transplant Proc; 2006 Apr; 38(3):751-2. PubMed ID: 16647462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
    Kyllönen LE; Salmela KT
    Transplantation; 2006 Apr; 81(7):1010-5. PubMed ID: 16612277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of c2 monitoring in prediction of diastolic dysfunction in renal transplant recipients.
    Kirkpantur A; Yilmaz R; Abali G; Arici M; Altun B; Aki T; Erkan I; Bakkaloglu M; Yasavul U; Turgan C
    Transplant Proc; 2008; 40(1):171-3. PubMed ID: 18261577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
    Carstens J
    Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine therapeutic monitoring with Cmax in kidney transplant recipients: does it fit for all populations?
    El-Agroudy AE; Ismail AM; Nassar M; Ghoneim MA
    Exp Clin Transplant; 2008 Dec; 6(4):282-6. PubMed ID: 19338490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
    Davies RA; Veinot JP; Williams K; Haddad H; Baker A; Donaldson J; Pugliese C; Struthers C; Masters RG; Hendry PJ; Mesana T
    Transplant Proc; 2007 Dec; 39(10):3334-9. PubMed ID: 18089382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.